Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1000100 | 0.84 | PKM (0.45) | MAPTALDH1A1MEN1KMT2AHTT | |
| SCHEMBL30038671 | 0.82 | MAPK1 (0.44) | MAPTALDH1A1MEN1KMT2AHTT | |
| SCHEMBL14387490 | 0.80 | ALOX15 (0.42) | MAPTALDH1A1MEN1KMT2AHTT | |
| SCHEMBL30424951 | 0.78 | MAPT (0.42) | MAPTALDH1A1MEN1KMT2AHTT | |
| SCHEMBL16244483 | 0.78 | MAPT (0.42) | MAPTALDH1A1MEN1KMT2AHTT | |
| SCHEMBL27255556 | 0.77 | ALDH1A1 (0.43) | MAPTALDH1A1MEN1KMT2AHTT | |
| SCHEMBL30038303 | 0.77 | MAPT (0.43) | MAPTALDH1A1MEN1KMT2AHTT | |
| SCHEMBL31160116 | 0.77 | ALDH1A1 (0.43) | MAPTALDH1A1MEN1KMT2AHTT | |
| SCHEMBL27162819 | 0.77 | MAPT (0.37) | MAPTALDH1A1MEN1KMT2AHTT | |
| SCHEMBL30039907 | 0.77 | ALDH1A1 (0.40) | MAPTALDH1A1MEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3412675-A1 | IMIDAZOPYRROLIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2018-12-12 | — | — | EP | disclosed |
| US-9890166-B2 | Imidazopyrrolidine derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2018-02-13 | — | — | US | disclosed |
| EP-3004108-B1 | PYRAZOLO-PYRROLIDIN-4-ONE DERIVATIVES AS BET INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2017-10-18 | — | — | EP | disclosed |
| US-9624247-B2 | Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-20160108047-A1 | IMIDAZOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| US-20160102107-A1 | PYRAZOLO-PYRROLIDIN-4-ONE DERIVATIVES AS BET INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2016-04-14 | — | — | US | disclosed |
| EP-3004108-A1 | PYRAZOLO-PYRROLIDIN-4-ONE DERIVATIVES AS BET INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2016-04-13 | — | — | EP | disclosed |
| EP-3004109-A1 | IMIDAZOPYRROLIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014191906-A1 | PYRAZOLO-PYRROLIDIN-4-ONE DERIVATIVES AS BET INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-12-04 | — | — | WO | disclosed |
| WO-2014191894-A1 | IMIDAZOPYRROLIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108047-A1 | IMIDAZOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | TPMT, REN, IL5 | MAPT 1394/4885ALDH1A1 401/4885MEN1 1363/4885 |
| US-20160102107-A1 | PYRAZOLO-PYRROLIDIN-4-ONE DERIVATIVES AS BET INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | BET1, BRD4, PHKB | MAPT 863/4885ALDH1A1 2852/4885MEN1 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.